The goal of the regional approaches for eradicating tuberculosis (rafet) activity is to reduce the burden of tuberculosis (TB), particularly drug-resistant tuberculosis (DR-TB), in the central asia…

The $3,595,735 Cooperative Agreement awarded by the U.S. Agency for International Development (USAID) under the USAID Foreign Assistance for Programs Overseas (CFDA 98.001) federal grant program aims to reduce the burden of tuberculosis (TB), particularly drug-resistant TB, in the Central Asia region within five years. The award, granted to the Dutch non-profit organization Koninklijke Nederlandse Centrale Vereniging Tot Bestrijding DER Tuberculose (Kncv), will support technical expertise, capacity building, and implementation of interventions to combat TB in Kazakhstan. Kncv, a foundation specializing in TB elimination and healthcare initiatives, has a strong track record of partnering with U.S. federal agencies on global health programs, including previous sub-grant awards with Management Sciences For Health, Inc. and The Johns Hopkins University for TB elimination efforts in Ethiopia, India, and Kazakhstan.

The goal of the regional approaches for eradicating tuberculosis (rafet) activity is to reduce the burden of tuberculosis (TB), particularly drug-resistant tuberculosis (DR-TB), in the central asia region within five years.